Symbols

CANF

Can-fite Biopharma·AMEX

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 1

Bearish signal 0

Consensus Rating "Strong Buy"

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CANF

Can-Fite Biopharma Ltd.

A company that developing small molecule therapeutics to treat autoimmune-inflammatory, oncological and ophthalmic diseases

Industry

Pharmaceutical

Established Date

09/11/1994

Listing Date

11/19/2013

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.canfite.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

26 Ben Gurion Street, Ramat Gan, 5257346, Israel

Business

Advanced clinical-stage biopharmaceutical company.

Introduction

Can-fite Biopharma Ltd., was founded on September 11, 1994. The Company is an advanced clinical-stage biopharmaceutical company developing oral bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein-associated A3 adenosine receptor, or A3AR, as a therapeutic target. A3AR is highly expressed in pathological somatic cells such as inflammation and cancer cells, and low in normal cells, suggesting that this receptor may be a specific target for pharmacological intervention. The company's pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators targeting A3AR.

Company Financials

EPS

CANF has released its 2023 Q3 earnings. EPS was reported at -0.43, versus the expected -0.44, beating expectations. The chart below visualizes how CANF has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CANF has released its 2023 Q4 earnings report, with revenue of 155.00K, reflecting a YoY change of -21.32%, and net profit of -1.65M, showing a YoY change of 45.28%. The Sankey diagram below clearly presents CANF's revenue sources and cost distribution.